NIHR Biomedical Research Centre, Royal Liverpool & Broadgreen University Hospital Trust, Liverpool, UK.
Antiviral Res. 2010 Jan;85(1):176-89. doi: 10.1016/j.antiviral.2009.07.017. Epub 2009 Aug 7.
Current antiretroviral treatment has allowed HIV infection to become a chronic manageable condition with many HIV patients living longer. However, available antiretrovirals are not without limitations, for example the development of resistance and adverse effects. Consequently, new drugs in existing and novel classes are urgently required to provide viable treatment options to patients with few remaining choices. Darunavir, etravirine, maraviroc and raltegravir have been recently approved for treatment-experienced patients and other agents such as rilpivirine, vicriviroc and elvitegravir are currently under phase III study. Clinical studies are necessary to optimise potential treatment combinations and to manage drug-drug interactions to help avoid toxicity or therapy failure. This review aims to summarise the pharmacokinetics and key drug-drug interaction studies for newly available antiretrovirals and those in development. Further information regarding drug-drug interactions of well established antiretrovirals and those recently approved are readily available online at sites such as http://www.hiv-druginteractions.org, http://www.clinicaloptions.com/hiv, http://hivinsite.ucsf.edu. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010.
目前的抗逆转录病毒治疗已经使 HIV 感染成为一种可以长期控制的慢性病，许多 HIV 患者的寿命更长。然而，现有的抗逆转录病毒药物并非没有局限性，例如耐药性和不良反应的产生。因此，迫切需要新的药物来为那些选择有限的患者提供可行的治疗方案，这些药物包括现有和新型药物类别中的药物。达芦那韦、依曲韦林、马拉维若和雷特格韦已被批准用于治疗有经验的患者，而其他药物，如利匹韦林、vicriviroc 和elvitegravir，目前正在进行 III 期研究。临床研究对于优化潜在的治疗组合和管理药物相互作用以帮助避免毒性或治疗失败是必要的。这篇综述旨在总结新出现的和正在开发的抗逆转录病毒药物的药代动力学和关键药物相互作用研究。关于已确立的抗逆转录病毒药物和最近批准的药物的药物相互作用的更多信息，在像 http://www.hiv-druginteractions.org、http://www.clinicaloptions.com/hiv、http://hivinsite.ucsf.edu 这样的网站上都可以轻松获取。本文是抗病毒研究杂志第 25 周年特刊的一部分，该特刊纪念抗逆转录病毒药物发现和开发 25 周年，第 85 卷，第 1 期，2010 年。
